Press Release-Alphamab Oncology

English 中文简体中文繁体

English 中文简体中文繁体

News Press Release Media Report

Year:

Select

Press Release

19 June 2020

Alphamab Oncology and Sinovent Announce Partnership to Co-Develop the Combination Therapy of KN046 and XNW7201 Through cooperation with Sinovent, we look forward to realizing the synergy from the combination of KN046 and XNW7201, and achieving significant efficacy in the treatment of pancreatic cancer and othe...
10 June 2020

Collaborating in Innovative Medical R&D to combat the pandemic, Alphamab Oncology and Institut Pasteur Shanghai Announce Partnership to Co-develop COVID-19 Neutralizing Antibody We plan to partner with Institut Pasteur Shanghai by leveraging our proprietary antibody technology platform, extensive experiences in antibody drug R&D and established manufacturing plafrom to accele...
09 June 2020

Alphamab Oncology and Sanofi Enter Collaboration on KN026 in HER2+ Breast Cancer Current clinicals trials shown promising preliminary efficacy and excellent safety profile in late-stage breast cancer patients who have failed multiple treatments in China, laying a solid foundation ...
28 May 2020

Alphamab Oncology and Sunshine Lake expand partnership to accelerate the development of the combination therapy of KN046 and CT053 Since the preliminary safety and efficacy of KN046 were verified by multiple single drug clinical trials, we believe that it could show better efficacy in combination therapy.
25 May 2020

Dr. Ting Xu of Alphamab Oncology will attend Jefferies Global Healthcare Conference Dr. Ting Xu will have an interview with Jefferies Research Analyst on Tuesday, June 2, 2020 at 8:00 (Eastern Daylight Time).
23 May 2020

Alphamab Oncology and InxMed Announce Partnership to Develop Combination Therapy of KN046 and IN10018 Alphamab Oncology is actively exploring various combination therapies to unlock the great potential of KN046.
18 May 2020

Alphamab Oncology will Present Clinical Data for KN026 at the 2020 AACR Annual Meeting Leveraging tumor suppression and group PK simulation to construct model is one our attempts to determine RP2D in early clinical settings.
15 May 2020

Alphamab Oncology Announces Positive Clinical Data for Subcutaneous Injectable anti-PD-L1 Antibody KN035 at the 2020 ASCO Annual Meeting We look forward to bringing this highly anticipated subcutaneous injection inhibitor to market as soon as possible, to benefit more patients.
14 May 2020

Alphamab Oncology will Present Phase I Clinical Data of KN046 and KN026 at the 2020 ASCO Annual Meeting We are pleased to see that the latest clinical data further validate the safety and efficacy of KN046 and KN026, and that will continue to support the development of subsequent clinical trials.
13 May 2020

Alphamab Oncology Announces Four IND Application Approvals from NMPA CDE The approval of the four IND applications marks a new milestone for our continued efforts on expanding combo treatments.

13 14 15 16 17 18 19